← Eichor
Study identifier: NCT06669611 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

Condition: Nasopharyngeal Cancinoma (NPC)  ·  Sponsor: Sun Yat-sen University

PhasePhase 3
Planned participants242
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

We expect to conduct a clinical trial in recurrent and metastatic nasopharyngeal carcinoma patients to explore and compare the efficacy and safety of induction chemotherapy (TPC vs. GP) with combination therapy of Camrelizumab.

This description comes directly from the study's public registry record.

Talk to the study team

XIANG YANQUN  ·  02087343379  ·  xiangyq@sysucc.org.cn

Always discuss trial participation with your own doctor first.

Locations (1)

SunYat-senUGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06669611